Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010.
J Reprod Med
; 59(1-2): 7-12, 2014.
Article
em En
| MEDLINE
| ID: mdl-24597279
ABSTRACT
OBJECTIVE:
To present survival rates of high-risk gestational trophoblastic neoplasia (GTN) (FIGO score > 7) patients treated between 1995 and 2010 in the U.K. Death due to GTN is largely confined to patients with high-risk disease. In the U.K. a national system ensures that all patients are treated at only 2 specialist centers Charing Cross Hospital (CXH) in London and Weston Park Hospital (WPH) in Sheffield. STUDYDESIGN:
A total of 196 high-risk patients were identified using the CXH and WPH GTN databases, based on the risk score at the time of presentation.RESULTS:
In all, 140 CXH and 56 WPH high-risk patients were treated with EMA/CO (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) and MEA (methotrexate, etoposide, actinomycin D), respectively. The FIGO score at presentation ranged from 6-23. Eight patients (7from WPH and 1 from CXH) who were treated prior to 2002 as high-risk based on their pre-2002 scoring scored a 6 using FIGO 2002. Two (1%) patients died within 4 weeks of starting treatment (early death), 12 (6%) relapsed, and 9 patients subsequently died due to drug resistance. The overall survival was 94%, with a median follow-up of 4.69 years.CONCLUSION:
In the context of a national trophoblastic disease service, patients with high-risk GTN have an excellent prognosis with EMA/CO or MEA.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doença Trofoblástica Gestacional
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Pregnancy
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article